Targeting RNA splicing modulation: new perspectives for anticancer strategy?
Top Cited Papers
Open Access
- 30 January 2025
- journal article
- review article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 44 (1) , 1-22
Abstract
The excision of introns from pre-mRNA is a crucial process in the expression of the majority of genes. Alternative splicing allows a single gene to generate diverse mRNA and protein products. Aberrant RNA splicing is recognized as a molecular characteristic present in almost all types of tumors. Therefore, identifying cancer-specific subtypes from aberrant processing offers new opportunities for therapeutic development. Numerous splicing modulators, each utilizing different mechanisms, have been developed as promising anticancer therapies, some of which are in clinical trials. In this review, we summarize the splice-altered signatures of cancer cell transcriptomes and the contributions of splicing aberrations to tumorigenesis and progression. Especially, we discuss current and emerging RNA splicing-targeted strategies for cancer therapy, including pharmacological approaches and splice-switching antisense oligonucleotides (ASOs). Finally, we address the challenges and opportunities in translating these findings into clinical practice.Keywords
Funding Information
- Science and technology innovation team project of China Medical University,China (CXTD2022007, CXTD2022007)
- Liaoning Province Higher Education Scientific Research Funding Project,China (No. 2023JH2/20200008, No. 2023JH2/20200008, No. 2023JH2/20200008)
- Liaoning Province Higher Education Scientific Research Funding Project, China (No. JYTM20230128, No. JYTM20230128, No. JYTM20230128)
This publication has 232 references indexed in Scilit:
- Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cellsMolecular Cancer Therapeutics, 2009
- The Spliceosome: Design Principles of a Dynamic RNP MachineCell, 2009
- The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA SplicingJournal of Biological Chemistry, 2008
- Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNANature Chemical Biology, 2007
- Total Syntheses, Fragmentation Studies, and Antitumor/Antiproliferative Activities of FR901464 and Its Low Picomolar AnalogueJournal of the American Chemical Society, 2007
- Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt–dependent matrix metalloproteinase-9 expressionMolecular Cancer Therapeutics, 2006
- Phase II study of E7070 in patients with metastatic melanomaAnnals of Oncology, 2005
- Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107 II. Physico-chemical Properties and Structure ElucidationThe Journal of Antibiotics, 2004
- Assisted RNP assembly: SMN and PRMT5 complexes cooperate in the formation of spliceosomal UsnRNPsThe EMBO Journal, 2002
- New Antitumor Substances, FR901463, FR901464 and FR901465. II. Activities against Experimental Tumors in Mice and Mechanism of Action.The Journal of Antibiotics, 1996